ratio
total
drug
concentr
would
appear
limit
valu
unless
receptor
question
total
drug
level
shown
relev
absenc
link
literatur
evid
suggest
import
consid
free
drug
concentr
brain
ii
equilibrium
theori
free
drug
appli
cn
compart
iii
potenti
use
csf
drug
concentr
surrog
free
drug
concentr
brain
norind
u
haeberlein
comput
approach
predict
bloodbrain
distribut
adv
drug
deliv
rev
clark
de
silico
predict
bloodbrain
barrier
permeat
focuss
major
advanc
novel
solut
field
antivir
drug
develop
present
antivir
r
program
concentr
develop
drug
design
inhibit
action
viral
protein
increas
evid
host
cell
also
afford
import
target
therapeut
agent
antivir
exploit
host
respons
alreadi
exist
exampl
although
chemotherapi
avail
treatment
influenza
herp
simplex
varicellazoost
cytomegaloviru
respiratori
syncyti
viru
rsv
papilloma
hepat
b
hepat
c
hiv
infect
still
signific
unmet
medic
need
novel
drug
combat
diseas
perhap
greater
concern
need
drug
treat
newli
emerg
infect
exampl
sever
acut
respiratori
syndrom
sar
west
nile
viru
wnv
term
emerg
diseas
interest
outlook
present
paul
kellam
univers
colleg
london
http
wwwuclacuk
result
continu
improv
molecular
biochem
technolog
number
virus
associ
infect
detect
constantli
increas
illustr
recent
sar
outbreak
sarscov
unambigu
identifi
novemb
april
link
sarscov
diseas
establish
may
full
genom
sequenc
meanwhil
pfizer
http
wwwpfizercommainhtml
launch
drug
develop
program
sarscov
proteas
wade
blair
pfizer
report
antisarscov
compound
show
activ
vitro
retrovir
assay
pfizer
pursu
homolog
model
sarscov
proteas
base
human
rhinoviru
proteas
proteas
crystal
structur
current
lead
program
show
efficaci
cellular
replic
model
patrick
iversen
avi
biopharma
http
wwwavibiocomhomehtml
report
differ
develop
strategi
treat
sar
exploit
antisens
therapi
avi
biopharma
use
antisens
phosphorodiamid
morpholino
oligom
pmo
uncharg
stabl
target
cmyc
cancer
compani
current
nine
ongo
clinic
studi
research
efficaci
use
pmo
treatment
cancer
date
observ
seriou
advers
side
effect
patient
particip
clinic
studi
avibiopharma
decid
appli
pmo
technolog
field
antivir
translat
extrem
promis
research
program
furthermor
iversen
report
record
time
nine
month
progress
pmo
use
treatment
wnv
concept
phase
ib
clinic
trial
similarli
activ
variou
pmo
sever
flaviviru
model
eg
hepat
c
observ
summari
pmo
safe
effect
rapid
novel
antisens
technolog
show
promis
antivir
therapi
howev
one
potenti
problem
pmo
therapeut
agent
method
administr
stabl
state
pmo
uncharg
render
unsuit
oral
administr
although
rsv
affect
signific
number
infant
elderli
immunocompromis
peopl
patholog
viru
extens
research
malcolm
carter
arrow
therapeut
http
wwwarrowtcouk
gave
comprehens
overview
compound
develop
alreadi
use
treatment
rsv
obviou
reason
fusion
inhibitor
program
wyeth
http
wwwwyethcom
viropharma
http
wwwviropharmacom
bristolmy
squibb
http
wwwbmscom
hold
discontinu
arrow
therapeut
identifi
potent
promis
lead
seri
compound
repres
clinic
candid
enter
preclin
develop
clinic
trial
plan
earli
complet
novel
mode
action
panel
discuss
tackl
question
nucleosid
analog
exhaust
jp
somadossi
idenix
http
wwwidenixcom
r
schinazi
pharmasset
http
wwwpharmassetcom
emphas
continu
research
develop
novel
nucleosid
inhibitor
viral
polymeras
develop
novel
nucleosid
analog
remain
attract
prospect
futur
antivir
drug
discoveri
follow
reason
administ
oral
year
experi
nucleosid
chemistri
well
defin
pharmacolog
mechan
action
eas
product
low
protein
bind
potenti
low
drugdrug
interact
high
probabl
regulatori
approv
low
develop
cost
howev
k
powel
arrow
therapeut
rais
sever
clear
counterargu
need
highli
train
nucleosid
chemist
clearli
defin
toxicolog
potenti
virus
develop
resist
undoubtedli
nucleosid
inhibitor
becom
effici
frontlin
therapi
lifethreaten
viral
infect
eg
hiv
time
come
gener
new
drug
lower
viral
load
patient
also
erad
viru
host
applic
novel
intervent
strategi
hiv
hepat
c
particularli
well
cover
confer
david
stammer
univers
oxford
http
wwwoxacuk
report
success
applic
structurebas
design
nonnucleosid
revers
transcriptas
inhibitor
nnrti
treatment
hiv
nnrti
act
inhibit
hiv
revers
transcriptas
bind
nnrti
hiv
revers
transcriptas
induc
conform
chang
enzym
subsequ
introduc
steric
effect
inhibit
mode
action
hiv
revers
transcriptas
basi
third
gener
nnrti
eg
success
develop
akhter
molla
abbott
laboratori
http
wwwabbottcom
summar
clinic
result
kaletra
combin
two
hiv
proteas
inhibitor
pi
ritonavir
lopinavir
current
bestsel
hiv
drug
kaletra
well
toler
exhibit
signific
antivir
effect
singl
multipl
piexperienc
patient
molla
report
although
kaletra
greater
activ
pi
atazanavir
studi
indic
atazanavir
like
becom
largest
competitor
kaletra
hiv
drug
market
oncedaili
administr
atazanavir
uniqu
amongst
pi
low
level
lipidrel
side
effect
compar
five
market
pi
associ
drug
barney
koszalka
trimeri
http
wwwtrimeriscom
summar
new
field
hiventri
inhibitor
begin
host
cell
approach
present
insight
develop
ligand
promis
compound
appear
antagonist
spirodiketopiperazin
deriv
also
known
ddt
vol
februari
updat
confer
commenc
phase
clinic
trial
juli
addit
koszalka
summar
research
perform
inhibitor
glycoprotein
roch
recent
launch
march
fuzeon
peptid
drug
act
block
domain
interact
fuzeon
return
tcell
count
patient
almost
cellsmm
magic
number
clinician
howev
koszalka
advis
fuzeon
employ
earli
therapi
patient
abl
toler
side
effect
advers
reaction
occur
inject
site
exacerb
administr
twicedaili
inject
lead
discontinu
rate
treat
patient
secondgener
fusion
inhibitor
current
develop
show
vitro
activ
fuzeonresist
virus
worldwid
million
individu
infect
hepat
c
viru
hcv
current
treatment
hepat
c
restrict
ribavirin
howev
patient
infect
lifethreaten
viru
respond
therapi
underlin
serious
diseas
urgent
unmet
medic
need
altern
treatment
lack
cellular
replic
model
hcv
complic
research
novel
therapeut
agent
hcv
hcv
replicon
cell
system
recogn
current
gold
standard
hcv
research
nathaniel
brown
idenix
describ
idenix
design
develop
novel
treatment
hepat
c
rapidli
nucleosid
inhibitor
hcv
polymeras
show
efficaci
chimpanze
model
furthermor
fda
accept
phase
iii
clinic
trial
start
michael
cordingley
boehring
ingelheim
limit
http
www
boehringeringelheimcom
explain
develop
inhibitor
proteas
earli
promis
candid
next
gener
hepat
c
drug
final
structur
optim
cocrystal
studi
peptidelik
lead
structur
result
challeng
peptidomimet
approach
potent
activ
vitro
replicon
system
bioavail
chimpanze
phase
trial
demonstr
potent
activ
viral
drop
three
log
twoday
treatment
howev
routin
chronic
safeti
test
high
supratherapeut
dose
anim
identifi
advers
reaction
drug
boehring
ingelheim
current
studi
avail
preclin
data
determin
impact
clinic
develop
compound
bert
klebl
axxima
pharmaceut
http
wwwaxximacom
present
approach
base
identif
valid
hostcel
target
hepat
c
gastrointestin
glutathion
peroxidas
gigpx
specif
downregul
hcv
replicon
cell
valid
experi
use
replicon
system
reveal
ectop
overexpress
gigpx
lead
inhibit
rna
replic
gigpx
promot
contain
retinoid
acid
respons
element
addit
retinoid
acid
deriv
replicon
system
result
inhibit
gigpx
promot
therefor
retinoid
acid
market
drug
acn
could
provid
altern
medic
therapi
treat
hepat
c
particularli
nonrespond
although
panel
discuss
address
futur
nucleosid
inhibitor
attract
econom
perspect
current
r
effort
move
differ
direct
altern
viral
target
becom
key
target
research
host
cell
also
evolv
potenti
target
treatment
viral
infect
futur
antivir
drug
develop
hold
great
interest
look
forward
next
confer
updat
progress
excit
field
research
